Kalydeco; a drug for cystic fibrosis, has been approved by FDA

Cystic Fibrosis (Credit: A. D. A. M. / MedlinePlus)

U.S. Food and Drug Administration has recently approved the drug "Kalydeco" for the treatment of cystic fibrosis, which affects the lungs and digestive system.

“Kalydeco is the first available treatment that targets the defective CFTR protein, which is the underlying cause of cystic fibrosis,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “This is a breakthrough therapy for the cystic fibrosis community because current therapies only treat the symptoms of this genetic disease.”

From SayPeople,

As reported by FDA, Kalydeco was found effective in the treatment of cystic fibrosis, a disease which is life-shortening in nature and affects the lungs and digestive system. Cystic fibrosis affects almost 30,000 people in U.S. Kalydeco attacks on the defective protein causing cystic fibrosis in almost 4% of patients.

Kalydeco will be available in U.S. Pharmacies by this week as reported by Vertex Pharmaceuticals.

Source:

SayPeople